- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608996
Nesiritide in Hypertension (TENSE1)
Therapeutic Effects of BNP in Hypertensive Patients
Hypertension remains a global burden in cardiovascular disease leading to stroke, myocardial infarction, and heart failure. Its myocardial complications result from increased mechanical load on the heart. Under physiological conditions of increased myocardial load and resulting myocardial stretch, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) synthesis and secretion occur contributing to maintenance of optimal cardiorenal and blood pressure homeostasis. However, studies indicate that in subjects with cardiovascular diseases the biological structure of these hormones may be altered, thus reducing their favorable protective activities. New studies indicate that early and moderate hypertension is associated with a derangement of the natriuretic peptide system which is characterized by the lack of activation of biologically active ANP and BNP, while severe hypertension is characterized by cardiac release of altered molecular forms of ANP and BNP that have reduced biological properties and/or enhanced degradation.
The broad objective of this proposal is to advance the biology and therapeutics of the NPs with a special focus on the cardiac peptide BNP in human hypertension. Our proposal is based upon the biological properties of BNP (i.e. natriuretic, renin-angiotensin-aldosterone suppressing, vasodilating, anti-fibrotic, anti-hypertrophic and positive lusitropic), its mechanistic role in human hypertension, and thus its potential as an innovative chronic protein therapeutic to enhance the treatment of patients with hypertension. Importantly, BNP is an endocrine hormone normally produced by the human heart, and it has been approved for the treatment of acute heart failure in USA.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Alessandro Cataliotti, MD, PhD
- Phone Number: +47 23016807
- Email: alessandro.cataliotti@medisin.uio.no
Study Locations
-
-
-
Oslo, Norway, 0450
- Recruiting
- Oslo University Hospital, Ullevål hospital
-
Contact:
- Morten Rostrup, MD, PhD
-
Sub-Investigator:
- Kaja K Bergo, MD
-
Sub-Investigator:
- Morten Rostrup, MD, PhD
-
Sub-Investigator:
- Einar S Norden
-
Sub-Investigator:
- Ivar Sjaastad, MD, PhD
-
Oslo, Norway, 0424
- Not yet recruiting
- Oslo University Hopital, Rikshospitalet
-
Contact:
- Hassan Z Khiabani, MD, PhD
-
Sub-Investigator:
- Hassan Z Khiabani, MD, PhD
-
Strømmen, Norway, 1478
- Recruiting
- Akershus University Hospital
-
Contact:
- My HS Svensson, MD, PhD
-
Sub-Investigator:
- Helge Røsjø, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Office systolic blood pressure (SBP) ≥ 120 mmHg and treatment with at least one anti-hypertensive medication. Unchanged medication regimen the last two weeks prior to inclusion.
- Average day-time SBP > 115 on a 24-h ambulatory BP measurement at screening.
Exclusion Criteria:
- Congestive Heart Failure (any New York Heart Association class)
- Ejection Fraction ≤ 40 %
- Known, not appropriately treated, secondary hypertension
- Myocardial infarction within 3 months of screening
- Unstable angina within 14 days of screening, or any evidence of myocardial ischemia
- Pulmonary hypertension
- Aortic stenosis with maximum jet velocity > 2,5 m/s
- Other valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis or biopsy proven active myocarditis
- Sustained Ventricular Tachycardia or Ventricular Fibrillation within 14 days of screening
- Sustained Atrial Fibrillation
- Second or third degree atrioventricular block without a permanent cardiac pacemaker
- Cerebrovascular event within 3 months of screening, or other evidence of significantly compromised cerebral perfusion
- Proteinuria defined as albumin:creatinine ratio > 100 (equivalent to an excretion of > 1 g/day)
- Nephrotic syndrome
- Body Mass Index > 35
- Total bilirubin of > 25 µmol/L, aspartate aminotransferase or alanine aminotransferase 1.5 times the upper limit of normal range
- Renal insufficiency assessed by estimated glomerular filtration rate (GFR) < 30 ml/min
- Serum sodium of ≤ 135 mmol/L and ≥ 150 mmol/L
- Serum potassium of ≤ 3.5 mmol/L and ≥ 5.5 mmol/L
- Women taking hormonal contraceptives containing estrogens
- Pregnancy
- Patients on prolonged, i.e. more than 30 days, immunosuppressant therapy
- Patients with known, active malignancies
- Patients with orthostatic hypotension
- Participation in a trial with an investigational product within the previous three months
- Any contraindication listed on the Investigator's Brochure of the Investigational Medicinal Product
- Any reason why, in the opinion of the investigator, the patient should not participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Subcutaneous BNP
Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
|
This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
Other Names:
|
PLACEBO_COMPARATOR: Subcutaneous placebo
Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
|
For comparison to elucidate the true effect of nesiritide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in blood pressure (BP)
Time Frame: 48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.
|
Office blood pressure and ambulatory blood pressure monitoring (ABPM) recordings will be used for the analysis
|
48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection(baseline data) up to 12 hours post last injection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Renal function as assessed by estimated glomerular filtration rate (eGFR)
Time Frame: 48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.
|
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin C equation will be used to calculate estimated glomerular filtration rate (eGFR).
|
48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.
|
Hormonal changes assessed by aldosterone, atrial natriuretic peptide (ANP), N Terminal-ANP, BNP, N Terminal-proBNP, C-type natriuretic peptide and cyclic guanosyl monophosphate.
Time Frame: 48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.
|
Will be measured in plasma, and all but aldosterone in urine Collections.
|
48 hours, from day 1 to day 2. Specifically, it will be assessed before first injection (baseline data) up to 12 hours post last injection.
|
Number of participants with treatment-related adverse events defined as all untoward and unintended responses to the treatment related to any dose administered.
Time Frame: 48 hours, from day 1 to day 2. Specifically, it will be assessed after first injection, up to 12 hours post last injection. A second determination will be done within 3 weeks after last injection (21 days assessment).
|
48 hours, from day 1 to day 2. Specifically, it will be assessed after first injection, up to 12 hours post last injection. A second determination will be done within 3 weeks after last injection (21 days assessment).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alessandro Cataliotti, MD, PhD, Oslo University Hospital and University of Oslo
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-000577-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Nesiritide
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedLeft Ventricular Diastolic DysfunctionUnited States
-
Janssen Pharmaceutical K.K.CompletedHeart Failure, CongestiveJapan
-
Mayo ClinicNational Institutes of Health (NIH)Completed
-
Xian-Janssen Pharmaceutical Ltd.CompletedCongestive Heart Failure | Heart DecompensationChina
-
Mayo ClinicScios, Inc.CompletedKidney Diseases | Congestive Heart Failure | CardiomyopathyUnited States
-
Ejaz, Abulate A, MDUnknownCardiovascular Disease | Death | Acute Renal FailureUnited States
-
University of Wisconsin, MadisonScios, Inc.CompletedHeart Failure, CongestiveUnited States
-
The Baruch Padeh Medical Center, PoriyaUnknownCoronary Artery DiseaseIsrael
-
Scios, Inc.CompletedHeart Failure, Congestive | Heart Decompensation
-
Shanghai Zhongshan HospitalUnknownCongestive Heart Failure | Mechanical Ventilation | Cardiac Function | Using Nesiritide | Venous ReturnChina